MAMMAL is especially interesting for cancer drug discovery because cancer research is naturally multimodal. A single oncology question can involve a tumor cell line, a drug molecule, a target protein, a gene-expression profile, toxicity signals, and experimental response data. IBM Research's Molecular Aligned Multi-Modal Architecture and Language, known as MAMMAL, is designed to bring several of those inputs into one biomedical foundation model.

The Nature portfolio article "MAMMAL - Molecular Aligned Multi-Modal Architecture and Language for biomedical discovery" reports that MAMMAL was trained on about 2 billion samples across protein and antibody sequences, small molecules, and gene expression profiles. That foundation makes it relevant to searches like MAMMAL cancer drug discovery, AI cancer research, gene expression drug response prediction, and SMILES protein drug-target interaction.

Why Cancer Drug Discovery Needs Multimodal AI

Cancer is not only a disease of abnormal cell growth. It is also a disease of altered signaling networks, genomic instability, immune evasion, tissue context, drug resistance, and cellular adaptation. A model that only sees one representation may miss important relationships. For example, a molecule can look promising chemically but fail in a particular cell context. A target can look biologically important but be hard to drug safely. A cell line can appear sensitive in one assay and resistant under different conditions.

Multimodal AI for oncology tries to connect these pieces. In MAMMAL's case, the model can represent proteins, small molecules, and gene expression profiles through a common task framework. That creates a path for studying how a drug candidate, a biological target, and a cancer cell state relate to one another.

Gene Expression And Cancer Drug Response

One of the most relevant MAMMAL use cases for oncology is cancer drug response prediction. The Nature article discusses benchmarks based on drug response resources such as GDSC, where researchers study how cancer cell lines respond to different drugs. In these workflows, a model may receive a drug representation and a gene-expression profile, then predict a response value such as IC50.

Gene-expression profiles help describe what a cancer cell is doing at the molecular level. Some genes may be highly active, others suppressed, and those patterns can influence whether a drug is likely to be effective. MAMMAL's ability to work with gene-expression inputs alongside drug representations is one reason it is relevant to precision oncology research.

SMILES Strings And Small-Molecule Research

Small molecules are often represented with SMILES strings, a compact text format for chemical structure. Many machine learning drug discovery workflows use SMILES because they are easy to store, tokenize, and combine with other data. MAMMAL can use small-molecule representations in tasks such as toxicity prediction, blood-brain barrier prediction, drug-target interaction, and drug response modeling.

For cancer research, SMILES-based inputs matter because many oncology therapies are small molecules. Kinase inhibitors, proteasome inhibitors, and many targeted therapies can be represented this way. When paired with gene-expression profiles or target protein sequences, SMILES inputs can help researchers ask more biologically grounded questions about candidate treatments.

Proteins, Targets, And Drug-Target Interaction

Most cancer therapies act through biological targets. Those targets are often proteins involved in cell signaling, DNA repair, immune regulation, apoptosis, or metabolism. MAMMAL includes protein sequence capabilities, which makes it useful for tasks involving protein-protein interactions and drug-target interaction prediction.

Drug-target interaction prediction is a core machine learning drug discovery task. A researcher may want to know whether a candidate molecule is likely to bind a protein target, or how strongly it might bind. MAMMAL's multimodal prompt structure allows protein and molecule inputs to be placed together for task-specific modeling.

Antibody Design And Oncology

Antibodies are central to modern cancer therapy, including checkpoint inhibitors, HER2-targeting therapies, antibody-drug conjugates, and bispecific approaches. The MAMMAL paper reports results on antibody-related tasks, including antibody-antigen binding and antibody infilling. In an antibody-antigen binding benchmark, the paper reports that fine-tuned MAMMAL prediction scores outperformed AlphaFold3 confidence scores in five of seven antigen targets when those confidence scores were used as a proxy for binding likelihood.

This does not make MAMMAL a replacement for structure modeling, binding assays, or clinical development. It does suggest that multimodal sequence-based models may become useful components in antibody discovery workflows, especially when paired with experimental validation.

How Researchers Can Start Exploring MAMMAL

The pretrained model is available on Hugging Face, and the official implementation is available in the BiomedSciAI/biomed-multi-alignment GitHub repository. The repository includes examples for drug-target interaction and cell-line drug response, which are the most directly relevant examples for cancer drug discovery.

If you are new to the model, start with our practical guide on how to use MAMMAL. If you want the nontechnical overview first, read What Is MAMMAL AI?.

What Patients And Advocates Should Know

For patients, MAMMAL should be understood as a research model, not a treatment recommendation engine. Its value is in helping scientists explore questions faster and across more forms of biomedical data. A model can help prioritize experiments, but clinical care still depends on physicians, validated evidence, approved therapies, and patient-specific context.

For advocates and supporters of cancer research, MAMMAL is a good example of where AI in oncology is heading. The field is moving beyond single-purpose models toward systems that can connect molecules, proteins, omics, and disease behavior. That shift may help researchers identify promising hypotheses earlier and use lab resources more efficiently.

The Bottom Line

MAMMAL matters because cancer drug discovery needs models that understand more than one slice of biology. By bringing together gene expression, SMILES strings, proteins, antibodies, classification, regression, and generative tasks, MAMMAL offers a public foundation for multimodal biomedical discovery research.

Follow the Cure Cancer With AI blog for more explainers on AI cancer research, precision oncology, and machine learning drug discovery. You can also learn more about Cure Cancer With AI and why we track tools like MAMMAL for readers who want research context without medical hype.